Hyperlipidemia, familial combined, LPL related

This Phase 3 trial will test whether a combination of three cholesterol-lowering drugs—bempedoic acid, ezetimibe, and a high-intensity statin—can reduce and stabilize plaque buildup in the coronary arteries. The study enrolls 103 adults with coronary atherosclerosis who have neve…

This trial tests whether EDP167, an experimental RNA drug, can safely lower triglycerides and other harmful fats in the blood of adults with mixed dyslipidemia. Participants receive one of three doses of EDP167 or a placebo as an injection every 12 weeks, alongside their usual st…

This Phase 3 trial tests a new drug called QLC7401 in about 780 adults with high cholesterol that remains high despite standard therapy. Participants will receive either QLC7401 or a placebo, added to their current cholesterol medications. The main goal is to see if QLC7401 can s…

This study tests whether a new omega-3 supplement called Ruby-O, made from phospholipids, raises omega-3 levels in the blood more effectively than standard omega-3 supplements. About 105 adults with mixed dyslipidemia (abnormal blood fats) who are already on statin therapy will t…

This early-stage trial will test a new drug formulation (AD-117) for mixed dyslipidemia, a condition involving high cholesterol and triglycerides. Sixty healthy adults will receive a single dose of either the new or a reference formulation to compare how the body processes each. …